Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Struthers Richard Scott | President & CEO | May 08 '24 | Option Exercise | 9.28 | 107,448 | 997,117 | 364,933 | May 10 04:57 PM | Struthers Richard Scott | President & CEO | May 08 '24 | Sale | 49.40 | 107,448 | 5,307,931 | 257,485 | May 10 04:57 PM | Pizzuti Dana | Chief Med and Dev Officer | Apr 15 '24 | Option Exercise | 16.89 | 14,375 | 242,794 | 42,161 | Apr 17 04:36 PM | Struthers Richard Scott | President & CEO | Apr 15 '24 | Option Exercise | 1.91 | 20,000 | 38,200 | 257,835 | Apr 17 04:30 PM | Pizzuti Dana | Chief Med and Dev Officer | Apr 15 '24 | Sale | 44.47 | 14,375 | 639,256 | 27,786 | Apr 17 04:36 PM | Struthers Richard Scott | President & CEO | Apr 04 '24 | Option Exercise | 9.28 | 40,951 | 380,025 | 278,786 | Apr 08 05:09 PM | Struthers Richard Scott | President & CEO | Apr 04 '24 | Sale | 49.17 | 40,951 | 2,013,561 | 237,835 | Apr 08 05:09 PM | Okey Stephanie | Director | Mar 28 '24 | Option Exercise | 18.29 | 17,500 | 320,075 | 23,500 | Apr 02 04:35 PM | Okey Stephanie | Director | Mar 28 '24 | Sale | 46.38 | 17,500 | 811,650 | 6,000 | Apr 02 04:35 PM | Knight Jeff E. | Chief Operating Officer | Mar 22 '24 | Option Exercise | 23.98 | 30,000 | 719,400 | 84,939 | Mar 26 04:30 PM | Knight Jeff E. | Chief Operating Officer | Mar 22 '24 | Sale | 44.31 | 32,359 | 1,433,675 | 52,580 | Mar 26 04:30 PM | Fust Matthew K | Director | Mar 20 '24 | Option Exercise | 20.92 | 60,000 | 1,254,975 | 36,036 | Mar 22 04:31 PM | Pizzuti Dana | Chief Med and Dev Officer | Mar 20 '24 | Option Exercise | 16.89 | 14,375 | 242,794 | 38,500 | Mar 22 04:52 PM | Fust Matthew K | Director | Mar 20 '24 | Sale | 44.14 | 60,000 | 2,648,150 | 18,536 | Mar 22 04:31 PM | Pizzuti Dana | Chief Med and Dev Officer | Mar 20 '24 | Sale | 44.06 | 15,089 | 664,763 | 27,786 | Mar 22 04:52 PM | Wilson Marc | CFO | Mar 19 '24 | Sale | 42.91 | 6,942 | 297,881 | 110,630 | Mar 20 06:32 PM | Betz Stephen F. | Chief Scientific Officer | Jan 25 '24 | Sale | 37.26 | 3,000 | 111,780 | 73,298 | Jan 26 05:50 PM | Betz Stephen F. | Chief Scientific Officer | Jan 10 '24 | Sale | 37.65 | 3,000 | 112,950 | 76,298 | Jan 12 04:12 PM | Pizzuti Dana | Chief Med and Dev Officer | Jan 03 '24 | Option Exercise | 16.89 | 14,375 | 242,794 | 20,286 | Jan 04 04:45 PM | Pizzuti Dana | Chief Med and Dev Officer | Jan 03 '24 | Sale | 35.00 | 14,375 | 503,125 | 5,911 | Jan 04 04:45 PM | Wilson Marc | CFO | Jan 02 '24 | Option Exercise | 9.28 | 10,000 | 92,800 | 106,055 | Jan 04 04:43 PM | Wilson Marc | CFO | Jan 02 '24 | Sale | 35.47 | 10,000 | 354,700 | 96,055 | Jan 04 04:43 PM | Betz Stephen F. | Chief Scientific Officer | Dec 26 '23 | Sale | 35.89 | 3,000 | 107,670 | 79,298 | Dec 27 05:20 PM | Pizzuti Dana | Chief Med and Dev Officer | Dec 21 '23 | Option Exercise | 16.89 | 9,583 | 161,857 | 15,494 | Dec 22 06:45 PM | Pizzuti Dana | Chief Med and Dev Officer | Dec 21 '23 | Sale | 34.57 | 9,583 | 331,284 | 5,911 | Dec 22 06:45 PM | Betz Stephen F. | Chief Scientific Officer | Dec 11 '23 | Sale | 32.87 | 3,000 | 98,610 | 82,298 | Dec 13 04:44 PM | Betz Stephen F. | Chief Scientific Officer | Nov 27 '23 | Sale | 31.84 | 3,000 | 95,520 | 85,298 | Nov 29 04:31 PM | Struthers Richard Scott | President & CEO | Nov 09 '23 | Option Exercise | 1.91 | 50,000 | 95,500 | 185,522 | Nov 13 04:33 PM | Struthers Richard Scott | President & CEO | Nov 03 '23 | Option Exercise | 9.28 | 199,082 | 1,847,481 | 334,604 | Nov 06 06:02 PM | Struthers Richard Scott | President & CEO | Nov 03 '23 | Sale | 30.56 | 199,082 | 6,083,946 | 135,522 | Nov 06 06:02 PM | Struthers Richard Scott | President & CEO | Nov 02 '23 | Option Exercise | 9.28 | 918 | 8,519 | 136,440 | Nov 06 06:02 PM | Struthers Richard Scott | President & CEO | Nov 02 '23 | Sale | 29.95 | 918 | 27,494 | 135,522 | Nov 06 06:02 PM | Wilson Marc | CFO | Nov 01 '23 | Option Exercise | 9.28 | 10,000 | 92,800 | 105,601 | Nov 03 07:38 PM | Wilson Marc | CFO | Nov 01 '23 | Sale | 28.75 | 10,000 | 287,500 | 95,601 | Nov 03 07:38 PM | Krasner Alan Seth | Chief Medical Officer | Oct 17 '23 | Option Exercise | 12.01 | 7,000 | 84,070 | 50,210 | Oct 19 05:01 PM | Krasner Alan Seth | Chief Medical Officer | Oct 17 '23 | Sale | 30.00 | 7,000 | 210,000 | 43,210 | Oct 19 05:01 PM | Struthers Richard Scott | President & CEO | Aug 14 '23 | Option Exercise | 1.91 | 10,000 | 19,100 | 135,522 | Aug 16 04:30 PM | Struthers Richard Scott | President & CEO | Jul 13 '23 | Sale | 20.35 | 14,157 | 288,095 | 630,805 | Jul 13 04:56 PM | Struthers Richard Scott | President & CEO | Jul 12 '23 | Sale | 20.17 | 11,459 | 231,128 | 644,962 | Jul 13 04:56 PM | Struthers Richard Scott | President & CEO | Jul 11 '23 | Sale | 20.14 | 24,384 | 491,094 | 656,421 | Jul 13 04:56 PM | Wilson Marc | CFO | Jun 20 '23 | Option Exercise | 9.28 | 20,000 | 185,600 | 115,158 | Jun 21 05:32 PM | Wilson Marc | CFO | Jun 20 '23 | Sale | 19.97 | 30,922 | 617,403 | 95,158 | Jun 21 05:32 PM | Struthers Richard Scott | President & CEO | Jun 16 '23 | Sale | 20.81 | 50,000 | 1,040,500 | 680,805 | Jun 21 05:27 PM | Vivaldi Coelho Rogerio | Director | Jun 08 '23 | Buy | 22.06 | 5,000 | 110,300 | 5,000 | Jun 09 08:00 AM |
|